Alliqua Appoints Perry A. Karsen to Board of Directors

            Alliqua Appoints Perry A. Karsen to Board of Directors

PR Newswire

LANGHORNE, Pennsylvania, December 4, 2013

LANGHORNE, Pennsylvania, December 4, 2013 /PRNewswire/ --

CEO of Celgene Cellular Therapeutics To Add Further Depth and Value to
Alliqua's Board

Increases Size of Board to Nine Members

Alliqua, Inc. (OTCQB:ALQAD) ("Alliqua" or the "Company") has appointed Perry
A. Karsen to its Board of Directors, increasing the size of the Board to nine
members.

Mr. Karsen, age 58, is Chief Executive Officer of Celgene Cellular
Therapeutics, a wholly owned subsidiary of Celgene Corporation, for which Mr.
Karsen also serves as Executive Vice President and Chief Operations Officer.

Mr. Karsen said, "Last month, I was pleased to help oversee the licensing of
advanced wound care products, Biovance® and Extracellular Matrix (ECM), from
Celgene Cellular Therapeutics to Alliqua. I am impressed by Alliqua's existing
suite of wound care products and I look forward to working with Alliqua's
management as Alliqua expands its sales, marketing and distribution
initiatives."

David Johnson, Chief Executive Officer of Alliqua, said, "As part of our
transaction with Celgene that was publicly announced on November 19, Celgene
received a right to appoint a director to our Board of Directors. I am
delighted that Perry Karsen has agreed to assume this role. He possesses a
profound knowledge of the wound care space, and has demonstrated a deep
commitment to its further development. We are privileged to have him help us
as we continue to pursue our corporate goals."

About Alliqua, Inc.

Alliqua, Inc. (ALQAD) ("Alliqua") is a biopharmaceutical company focused on
the development, manufacturing, and distribution of proprietary transdermal
wound care and drug delivery technologies. Alliqua's technology platform
produces hydrogels, a 3-dimensional cross-linked network of water soluble
polymers capable of numerous chemical configurations.

Alliqua currently markets its line of 510(k) FDA-approved hydrogel products
for wound care under the SilverSeal®brand, as well as the sorbion sachet S
and sorbion sana wound care products. Alliqua's electron beam production
process, located at its 16,000 square foot GMP manufacturing facility in
Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety
of hydrogels. Alliqua's hydrogels can be customized for various transdermal
applications to address market opportunities in the treatment of wounds as
well as the delivery of numerous drugs or other agents for pharmaceutical and
cosmetic industries. Additionally, Alliqua's drug delivery platform, in
combination with certain active pharmaceutical ingredients, can provide
pharmaceutical companies with a transdermal technology to enhance patient
compliance and potentially extend the patent life of valuable drug franchises.

For additional information, please visit http://www.alliqua.com. To receive
future press releases via email, please visit
http://ir.stockpr.com/alliqua/email-alerts.

Any statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements
are generally identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or "project"
or the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to numerous
factors and uncertainties outside of our control that can make such statements
untrue, including, but not limited to, inadequate capital, adverse economic
conditions, intense competition, lack of meaningful research results, entry of
new competitors and products, adverse federal, state and local government
regulation, termination of contracts or agreements, technological obsolescence
of our products, technical problems with our research and products, price
increases for supplies and components, inability to carry out research,
development and commercialization plans, loss or retirement of key executives
and research scientists and other specific risks. We currently have no
commercial products intended to diagnose, treat, prevent or cure any disease.
The statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration. There can be no assurance that further
research and development, and/or whether clinical trial results, if any, will
validate and support the results of our preliminary research and studies.
Further, there can be no assurance that the necessary regulatory approvals
will be obtained or that we will be able to develop new products on the basis
of our technologies. In addition, other factors that could cause actual
results to differ materially are discussed in our Annual Report on Form 10-K/A
filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with
the SEC. Investors and security holders are urged to read these documents free
of charge on the SEC's web site at http://www.sec.gov. We undertake no
obligation to publicly update or revise our forward-looking statements as a
result of new information, future events or otherwise.

Contact:

Alliqua, Inc.
Brian M. Posner, +1-215-702-8550
Chief Financial Officer
bposner@alliqua.com

or
Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider, +1-212-825-3210
cschneider@dgicomm.com
or
Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj, +1-212-825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com

SOURCE Alliqua, Inc.